Interv Akut Kardiol. 2017;16(2):71-74 | DOI: 10.36290/kar.2017.011

Caheter ablation for atrial fibrillation in prevention of stroke

Martin Fiala
Oddělení kardiologie, Centrum kardiovaskulární péče, Brno
Interní kardiologická klinika, FN a MU Brno

Prevention of thromboembolic complications represents a fundamental component of treatment in patients with atrial fibrillation

(AF). Successful AF catheter ablation, via restoration of sinus rhythm and recovery of normal left atrial appendage contractions,

has the potential to reverse the risk of ischemic stroke to the level in population without AF. In addition, the ablation effects include

reversal of hemodynamic and functional impairment hidden behind the cardiovascular mortality, specifically in patients

with persistent AF. Deeper understanding of causal links between AF and the risk of thromboembolic event would help better

stratification of patients who can safely terminate anticoagulation after ablation.

Keywords: atrial fibrillation, thromboembolism, stroke, catheter ablation

Accepted: April 24, 2017; Published: May 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Fiala M. Caheter ablation for atrial fibrillation in prevention of stroke. Interv Akut Kardiol. 2017;16(2):71-74. doi: 10.36290/kar.2017.011.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. The Atrial Fibrillation Follow up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-1833. Go to original source... Go to PubMed...
    2. The AFFIRM Investigators. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Circulation 2004; 109: 1509-1513. Go to original source... Go to PubMed...
    3. Wazni OM, Marrouche NF, Martin DO, et al. Radiofrequency ablation vs. antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA 2005; 293: 2634-2640. Go to original source... Go to PubMed...
    4. Pappone C, Augello G, Sala S, et al. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation. The APAF study. J Am Coll Cardiol 2006; 48: 2340-2347. Go to original source... Go to PubMed...
    5. Stabile G, Bertaglia E, Senatore G, et al. Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective multi-centre, randomized, controlled study (Catheter Ablation For The Cure Of Atrial Fibrillation Study). Eur Heart J 2006; 27: 216-221. Go to original source... Go to PubMed...
    6. Ja?s P, Cauchemez B, Macle L, et al. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. Circulation 2008; 118: 2498-2505. Go to original source... Go to PubMed...
    7. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC endorsed by the European Stroke Organization (ESO). Eur Heart J 2016; 37: 2893-2962. Go to original source... Go to PubMed...
    8. Wolf PA, D'Agostino RB, Belanger AJ, et al. Probability of stroke: a risk profile from the Framingham study. Stroke 1991; 22: 312-318. Go to original source... Go to PubMed...
    9. Wolf PA, Abbot RD, Kannel WB, et al. Atrial fibrillation as independent risk factor for stroke: The Framingham study. Stroke 1991; 22: 983-988. Go to original source... Go to PubMed...
    10. Petersen P, Boysen G, Godtfredsen J, et al. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989; 1: 175-179. Go to original source... Go to PubMed...
    11. The Boston area anticoagulation trial for atrial fibrillation investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990; 323: 1505-1511.
    12. Connolly SJ, Laupacis A, Gent M, et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. Final results. Circulation 1991; 84: 527-539. Go to original source...
    13. Stroke prevention in atrial fibrillation investigators. Stroke prevention in atrial fibrillation study. Final results. Circulation 1991; 84: 527-539.
    14. Ezekowitz M, Bridgers S, James K, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 1992; 327: 1406-1412. Go to original source... Go to PubMed...
    15. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342: 1255-1262. Go to original source...
    16. Lévy S, Maarek M, Coumel P, et al. Characterization of different subsets of atrial fibrillation in general practice in France. The ALFA Study. Circulation 1999; 99: 3028-3035. Go to original source... Go to PubMed...
    17. Connolly SJ, Ezekowitz MD, Eikelboom Y, et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151. Go to original source... Go to PubMed...
    18. Patel MR, Mahaffey KW, Garg J, et al. ROCKET-AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891. Go to original source... Go to PubMed...
    19. Connolly SJ, Eikelboom J, Joyner, et al. AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806-817. Go to original source... Go to PubMed...
    20. Granger CB, Alexander JH, McNurray JJ, et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Eng. J Med 2011; 365: 981-992. Go to original source... Go to PubMed...
    21. Holmes DR, Reddy VY, Turi ZG, et al. PROTECTAF Investigators. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomized non-inferiority trial. Lancet 2009; 374: 534-542. Go to original source... Go to PubMed...
    22. Lip GYH, Laroche C, Ioachim PM, et al. Prognosis and treatment of atrial fibrillation patients by European cardiologists: One Year Follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry). Eur Heart J 2014; 35: 3365-3376. Go to original source... Go to PubMed...
    23. Le Heuzey JY, Paziaud O, Piot O, et al. Cost of care distribution in atrial fibrillation patients: The COCAF Study. Am Heart J 2004; 147: 121-126. Go to original source... Go to PubMed...
    24. Nieuwlaat R, Prins MH, Le Heuzy JY, et al. Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation. Eur Heart J 2008; 29: 1181-1189. Go to original source... Go to PubMed...
    25. Edgerton Z, Perini HP, Horton R, et al. Hybrid procedure (endo/epicardial) versus standard manual procedure in patients undergoing ablation of longstanding persistent atrial fibrillation: results from a single center. J Cardiovasc Electrophysiol 2016; 27: 524-539. Go to original source... Go to PubMed...
    26. Bulková V, Fiala M, Havránek S, et al. Improvement in quality of life after catheter ablation for paroxysmal versus long-standing persistent atrial fibrillation: A prospective study with 3-year follow-up. J. Am. Heart. Assoc. 2014; 3: e000881. Go to original source... Go to PubMed...
    27. Jones DG, Haldar SK, Hussain W, et al. A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure. J. Am. Coll. Cardiol. 2013; 61: 1894-1903. Go to original source... Go to PubMed...
    28. Hunter RJ, Berriman TJ, Diab I, et al. A randomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart failure (the CAMTAF Trial). Circ. Arrhythm. Electrophysiol. 2014; 7: 31-38. Go to original source... Go to PubMed...
    29. Fiala M, Wichterle D, Bulková V, et al. A prospective evaluation of hemodynamics, functional status, and quality of life after radiofrequency catheter ablation of long-standing persistent atrial fibrillation. Europace. 2014; 16: 15-25. Go to original source... Go to PubMed...
    30. Mohanty S, Santangeli P, Mohanty P, et al. Catheter ablation of asymptomatic long-standing persistent atrial fibrillation: impact on quality of life, exercise performance, arrhythmia perception, and arrhythmia-free survival. J. Cardiovasc. Electrophysiol. 2014; 25: 1057-1064. Go to original source... Go to PubMed...
    31. Fiala M, Bulková V, Škňouřil L, et al. Functional improvement after successful catheter ablation for long-standing persistent atrial fibrillation. Europace. DOI:10.1093/europace/euw282 (ahead of print).
    32. Oral H, Chugh A, Özaydin M, et al. Risk of thromboembolic events after percutaneous left atrial radiofrequency ablation of atrial fibrillation. Circulation 2006; 114: 759-765. Go to original source... Go to PubMed...
    33. Nademanee K, Schwab MC, Kosar EM, et al. Clinical outcomes of catheter ablation for high-risk patients with atrial fibrillation. J Am Coll Cardiol 1008; 51: 843-849. Go to original source... Go to PubMed...
    34. Themistoclakis S, Corrado A, Marchlinski FE, et al. The risk of thromboembolism and need for oral anticoagulation after successful atrial fibrillation ablation. J Am Coll Cardiol 2010; 55: 735-743. Go to original source... Go to PubMed...
    35. Saad EB, d'Avila A, Costa IP, et al. Very low risk of thromboembolic events in patients undergoing successful catheter ablation of atrial fibrillation with a CHADS2 score <=3: a long-term outcome study. Circ Arrhythm Electrophysiol 2011; 4: 615-621. Go to original source... Go to PubMed...
    36. Yagishita A, Takahashi Y, Takahashi A, et al. Incidence of late thromboembolic events after catheter ablation of atrial fibrillation. Circ J 2011; 75: 2343-2349. Go to original source... Go to PubMed...
    37. Hunter RJ, McCready J, Diab I, et al. Maintenance of sinus rhythm with an ablation strategy in patients with atrial fibrillation is associated with a lower risk of stroke and death. Heart 2012; 98: 48-53. Go to original source... Go to PubMed...
    38. Lin YJ, Chao TF, Tsao HM, et al. Successful catheter ablation reduces the risk of cardiovascular events in atrial fibrillation patients with CHA2DS2-VASC risk score of 1 and higher. Europace 2013; 15: 676-684. Go to original source... Go to PubMed...
    39. Winkle RA, Mead RH, Engel G, et al. Discontinuing anticoagulation following successful atrial fibrillation ablation in patients with prior strokes. J Interv Card Electrophysiol 2014; 38: 147-53. Go to original source... Go to PubMed...
    40. Bunch TJ, May HT, Bair TL, et al. Atrial fibrillation ablation patients have long-term stroke rates similar to patients without atrial fibrillation regardless of CHADS2 score. Heart Rhythm 2013; 10: 1272-1277. Go to original source... Go to PubMed...
    41. Nührich JM, Kuck KH, Andersen D, et al. Oral anticoagulation is frequently discontinued after ablation of paroxysmal atrial fibrillation despite previous stroke: data form the German Ablation Registry. Clin Res Cardiol. 2015; 104: 463-470. Go to original source... Go to PubMed...
    42. Takigawa M, Takahashi A, Kuwahara T, et al. Late-phase thromboembolism after catheter ablation for paroxysmal atrial fibrillation. Circ J 2014; 78: 2394-2401. Go to original source... Go to PubMed...
    43. Karasoy D, Gislason GH, Hansen J, et al. Oral anticoagulation therapy after radiofrequency ablation of atrial fibrillation and the risk of thromboembolism and serious bleeding: long-term follow-up in nationwide cohort of Denmark. Eur Heart J 2015; 36: 307-314. Go to original source... Go to PubMed...
    44. Friberg L, Tabrizi F, Englund A. Catheter ablation for atrial fibrillation is associated with lower incidence of stroke and death: data from Swedish health registries. Eur Heart J 2016; 37: 2478-2487. Go to original source... Go to PubMed...
    45. Corradi D, Callegari D, Benussi S, et al. Regional left atrial interstitial remodeling in patients with chronic atrial fibrillation undergoing mitral-valve surgery. Virchow Arch 2004; 445: 498-505. Go to original source... Go to PubMed...
    46. Goldman ME, Pearce LA, Hart RG, et al. Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: I. Reduced flow velocity in the left atrial appendage (The Stroke Prevention in Atrial Fibrillation [SPAF-III] study). J Am Soc Echocardiogr 1999; 12: 1080-1087. Go to original source... Go to PubMed...
    47. Muellerleile K, Groth M, Steven D, et al. Cardiovascular magnetic resonance demonstrates reversible atrial dysfunction after catheter ablation of persistent atrial fibrillation. J Cardiovasc Electrophysiol 2013; 24: 762-767. Go to original source... Go to PubMed...
    48. Machino-Ohtsuka T, Seo Y, Ishizu T, et al. Significant improvement of left atrial and left atrial appendage function after catheter ablation for persistent atrial fibrillation. Circ. J. 2013; 77: 1695-1704. Go to original source... Go to PubMed...
    49. Donal E, Yamada H, Leclerq C, et al. The left atrial appendage, a small blind structure: a review of its echocardiographic evaluation and its critical role. Chest 2005; 128: 1853-1862. Go to original source... Go to PubMed...
    50. Daoud EG, Glotzer TV, Wyse DG, et al. Temporal relationship of atrial tachyarrhythmias, cerebrovascular events, and systemic emboli based on stored device data: a subgroup analysis of TRENDS. Heart Rhythm 2011; 8: 1416-1423. Go to original source... Go to PubMed...

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.